[1] |
Luu M, Frieden IJ. Haemangioma: clinical course, complications and management[J]. Br J Dermatol, 2013, 169(1): 20⁃30. DOI: 10.1111/bjd.12436.
|
[2] |
Drolet BA, Frommelt PC, Chamlin SL, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference[J]. Pediatrics, 2013, 131(1): 128⁃140. DOI: 10.1542/peds.2012⁃1691.
|
[3] |
Léauté⁃Labrèze C, Hoeger P, Mazereeuw⁃Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma[J]. N Engl J Med, 2015, 372(8): 735⁃746. DOI: 10.1056/NEJMoa1404710.
|
[4] |
Bauman NM, McCarter RJ, Guzzetta PC, et al. Propranolol vs prednisolone for symptomatic proliferating infantile hemangiomas: a randomized clinical trial[J]. JAMA Otolaryngol Head Neck Surg, 2014, 140(4): 323⁃330. DOI: 10.1001/jamaoto.2013.6723.
|
[5] |
Shehata N, Powell J, Dubois J, et al. Late rebound of infantile hemangioma after cessation of oral propranolol[J]. Pediatr Dermatol, 2013, 30(5): 587⁃591. DOI: 10.1111/pde.12190.
|
[6] |
Ábarzúa⁃Araya A, Navarrete⁃Dechent CP, Heusser F, et al. Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study[J]. J Am Acad Dermatol, 2014, 70(6): 1045⁃1049. DOI: 10.1016/j.jaad.2014.01. 905.
|
[7] |
MacIsaac ZM, Nayar HS, Gehris R, et al. Treatment for infantile hemangiomas: selection criteria, safety, and outcomes using oral propranolol during the early phase of propranolol use for hemangiomas[J]. J Craniofac Surg, 2016, 27(1): 159⁃162. DOI: 10.1097/SCS.0000000000002206.
|
[8] |
Hermans DJ, Maal TJ, Bergé SJ, et al. Three⁃dimensional stereophotogrammetry: a novel method in volumetric measurement of infantile hemangioma[J]. Pediatr Dermatol, 2014, 31(1): 118⁃122. DOI: 10.1111/pde.12224.
|
[9] |
Léauté⁃Labrèze C, de la Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649⁃2651. DOI: 10.1056/NEJMc0708819.
|
[10] |
Léauté⁃Labrèze C, de la Roque ED, Nacka F, et al. Double⁃blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants < 4 months of age[J]. Br J Dermatol, 2013, 169(1): 181⁃183. DOI: 10.1111/bjd.12217.
|
[11] |
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas[J]. Pediatrics, 2011, 128(2): e259⁃266. DOI: 10.1542/peds.2010⁃0029.
|
[12] |
Awadein A, Fakhry MA. Evaluation of intralesional propranolol for periocular capillary hemangioma[J]. Clin Ophthalmol, 2011, 5: 1135⁃1140. DOI: 10.2147/OPTH.S22909.
|
[13] |
杨舟, 李丽, 徐子刚, 等. 普萘洛尔治疗婴儿血管瘤的临床疗效及安全性[J]. 中华皮肤科杂志, 2012, 45(7): 466⁃469. DOI: 10.3760/cma.j.issn.0412⁃4030.2012.07.003.
|
[14] |
Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action[J]. Br J Dermatol, 2010, 163(2): 269⁃274. DOI: 10.1111/j.1365⁃2133. 2010.09848.x.
|
[15] |
Ahogo CK, Ezzedine K, Prey S, et al. Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol[J]. Br J Dermatol, 2013, 169(6): 1252⁃1256. DOI: 10.1111/bjd.12432.
|
[16] |
Chu DH, Castelo⁃Soccio L, Wan J, et al. Retrospective analysis of beta⁃blocker instituted for treatment of hemangiomas (RABBIT study)[J]. Clin Pediatr (Phila), 2014, 53(11): 1084⁃1090. DOI: 10.1177/0009922814535660.
|